Cue Return On Equity from 2010 to 2024
| CUE Stock | USD 1.55 0.10 6.06% |
Return On Equity | First Reported 2010-12-31 | Previous Quarter (1.37) | Current Value (1.44) | Quarterly Volatility 0.40761518 |
Check Cue Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cue main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.6 M, Interest Expense of 1.2 M or Selling General Administrative of 11.7 M, as well as many exotic indicators such as Price To Sales Ratio of 20.9, Dividend Yield of 0.0 or PTB Ratio of 3.09. Cue financial statements analysis is a perfect complement when working with Cue Biopharma Valuation or Volatility modules.
Cue | Return On Equity |
Latest Cue Biopharma's Return On Equity Growth Pattern
Below is the plot of the Return On Equity of Cue Biopharma over the last few years. Return on Equity is the amount of Cue Biopharma net income returned as a percentage of Cue Biopharma equity. Return on equity measures Cue Biopharma profitability by revealing how much profit Cue Biopharma generates with the money shareholders have invested. It is a measure of the profitability of a business in relation to the equity, calculated by dividing net income by shareholder's equity. Cue Biopharma's Return On Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cue Biopharma's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported -1.17 | 10 Years Trend |
|
Return On Equity |
| Timeline |
Cue Return On Equity Regression Statistics
| Arithmetic Mean | (0.61) | |
| Coefficient Of Variation | (66.29) | |
| Mean Deviation | 0.32 | |
| Median | (0.50) | |
| Standard Deviation | 0.41 | |
| Sample Variance | 0.17 | |
| Range | 1.162 | |
| R-Value | (0.83) | |
| Mean Square Error | 0.06 | |
| R-Squared | 0.69 | |
| Significance | 0.0001 | |
| Slope | (0.08) | |
| Total Sum of Squares | 2.33 |
Cue Return On Equity History
About Cue Biopharma Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Cue Biopharma income statement, its balance sheet, and the statement of cash flows. Cue Biopharma investors use historical funamental indicators, such as Cue Biopharma's Return On Equity, to determine how well the company is positioned to perform in the future. Although Cue Biopharma investors may use each financial statement separately, they are all related. The changes in Cue Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Cue Biopharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Cue Biopharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Cue Biopharma. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Equity | (1.37) | (1.44) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Cue Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Cue Biopharma's short interest history, or implied volatility extrapolated from Cue Biopharma options trading.
Pair Trading with Cue Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cue Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cue Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against Cue Stock
| 0.55 | DXCM | DexCom Inc | PairCorr |
| 0.53 | CI | Cigna Corp | PairCorr |
| 0.49 | EDAP | EDAP TMS SA Earnings Call Tomorrow | PairCorr |
| 0.47 | SERA | Sera Prognostics Downward Rally | PairCorr |
The ability to find closely correlated positions to Cue Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cue Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cue Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cue Biopharma to buy it.
The correlation of Cue Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cue Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cue Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cue Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Cue Biopharma Correlation against competitors. For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for Cue Stock analysis
When running Cue Biopharma's price analysis, check to measure Cue Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cue Biopharma is operating at the current time. Most of Cue Biopharma's value examination focuses on studying past and present price action to predict the probability of Cue Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cue Biopharma's price. Additionally, you may evaluate how the addition of Cue Biopharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |
Is Cue Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cue Biopharma. If investors know Cue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cue Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.07) | Revenue Per Share 0.149 | Quarterly Revenue Growth 8.182 | Return On Assets (0.47) | Return On Equity (1.18) |
The market value of Cue Biopharma is measured differently than its book value, which is the value of Cue that is recorded on the company's balance sheet. Investors also form their own opinion of Cue Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Cue Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cue Biopharma's market value can be influenced by many factors that don't directly affect Cue Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cue Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cue Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.